Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Cancers Année : 2021

Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma

Jérémy H Raymond
  • Fonction : Auteur
  • PersonId : 1139080
Tommy Billoux
  • Fonction : Auteur
  • PersonId : 1139081
Veronique Delmas
Lionel Larue
  • Fonction : Auteur
  • PersonId : 922897

Résumé

Purpose: To assess the efficiency of targeted radionuclide therapy (TRT), alone or in combination with MEK inhibitors (MEKi), in melanomas harboring constitutive MAPK/ERK activation responsible for tumor radioresistance. Methods: For TRT, we used a melanin radiotracer ([131I]ICF01012) currently in phase 1 clinical trial (NCT03784625). TRT alone or combined with MEKi was evaluated in three-dimensional melanoma spheroid models of human BRAFV600E SK-MEL-3, murine NRASQ61K 1007, and WT B16F10 melanomas. TRT in vivo biodistribution, dosimetry, efficiency, and molecular mechanisms were studied using the C57BL/6J-NRASQ61K 1007 syngeneic model. Results: TRT cooperated with MEKi to increase apoptosis in both BRAF- and NRAS-mutant spheroids. NRASQ61K spheroids were highly radiosensitive towards [131I]ICF01012-TRT. In mice bearing NRASQ61K 1007 melanoma, [131I]ICF01012 induced a significant extended survival (92 vs. 44 days, p < 0.0001), associated with a 93-Gy tumor deposit, and reduced lymph-node metastases. Comparative transcriptomic analyses confirmed a decrease in mitosis, proliferation, and metastasis signatures in TRT-treated vs. control tumors and suggest that TRT acts through an increase in oxidation and inflammation and P53 activation. Conclusion: Our data suggest that [131I]ICF01012-TRT and MEKi combination could be of benefit for advanced pigmented BRAF-mutant melanoma care and that [131I]ICF01012 alone could constitute a new potential NRAS-mutant melanoma treatment.
Fichier principal
Vignette du fichier
cancers-13-01421-v2(1).pdf (3.38 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03437826 , version 1 (20-11-2021)

Licence

Paternité

Identifiants

Citer

Hussein Akil, Mercedes Quintana, Jérémy H Raymond, Tommy Billoux, Valentin Benboubker, et al.. Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma. Cancers, 2021, 13 (6), pp.1421. ⟨10.3390/cancers13061421⟩. ⟨hal-03437826⟩
87 Consultations
24 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More